London – Advance Tests, a pioneer in advanced diagnostics, announced today the launch of LucentAD Complete in the UK, an innovative, multi-marker blood test for detecting early signs of Alzheimer’s Disease. Developed by Lucent Diagnostics, a commercial brand of Quanterix Corporation, this breakthrough test combines several biomarkers, including p-Tau 217, to enhance early detection in patients with cognitive symptoms.
The collaboration between Lucent Diagnostics and Advance Tests allows the test to be delivered to patients and healthcare providers in the UK from December 2nd, marking a significant milestone in accessible Alzheimer’s diagnostics.
“LucentAD Complete is a game-changer for early Alzheimer’s diagnosis in the UK,” said Dr. Karan Jutlla, Head of the Centre for Applied and Inclusive Health Research at the University of Wolverhampton. “By simplifying diagnostics, we’re helping more patients access critical care sooner, especially as new therapies for early-stage Alzheimer’s are becoming available.”
The test, which costs £695, is a cost-effective alternative to PET imaging and lumbar punctures, which can be significantly more expensive. It requires only a blood sample, eliminating the need for invasive CSF collection and costly imaging procedures, in line with Advance Tests’ mission to make life-saving diagnostics widely accessible.
“Having access to this sophisticated, non-invasive blood test is a game-changer for early Alzheimer’s diagnosis in the UK,” said Dr. Simon Worrell, Founder and Chief Medical Officer of Advance Tests. “Our work with Quanterix strengthens our commitment to removing barriers to early diagnosis, enabling timely treatment that could profoundly impact patients’ lives.”
The LucentAD Complete test meets the performance standards set by the Global CEO Initiative on Alzheimer’s Disease (CEOi) and the US Alzheimer’s Association (AA). It utilizes p-Tau 217 along with additional biomarkers—Aβ42/40, GFAP, and NfL—to improve amyloid detection over single biomarker tests, delivering a result that either rules in or rules out amyloid pathology for approximately 90% of cases.
Appointments for testing can be booked now either directly or by healthcare providers via www.advancetests.com, with appointments available from December 2nd 2024. The test will be available on a private basis at Advance Tests’ first clinic located on St Thomas Street, beside Guy’s Hospital opposite London Bridge station. Additional clinics are planned for cities across the UK to expand patient access to this transformative diagnostic tool.
“Advance Tests is committed to pioneering accessible diagnostic solutions worldwide, aiming to break down barriers to early disease detection,” said Stephen Simpson, spokesperson for Advance Tests. “Founded by four experienced leaders in diagnostics and healthcare innovation, Advance Tests’ team brings unparalleled expertise in the commercialization of cutting-edge technology.”
For more information, visit www.advancetests.com or contact stephen.simpson@advancetests.com.
Contact: Stephen Simpson, Advance Tests
stephen.simpson@advancetests.com
07792767529
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.